{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:22:57Z","timestamp":1784935377021,"version":"3.55.0"},"reference-count":38,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:p>Reports suggested the potential occurrence of peripheral neuropathies (PN) in patients treated with BRAF (BRAFi) and\/or MEK inhibitors (MEKi) for BRAF\u2010activated tumours. We aimed to better characterize these PN. We queried the French pharmacovigilance database for all cases of PN attributed to BRAFi and\/or MEKi. Fifteen patients were identified. Two main clinical PN phenotypes were seen. Six patients presented a length\u2010dependent, axonal polyneuropathy: symptoms were mostly sensory and affecting the lower limbs; management and outcome were variable. Nine patients developed a demyelinating polyradiculoneuropathy: symptoms affected the four limbs and included hypoesthesia, weakness and ataxia; cranial nerves were involved in four cases; most patients received intravenous immunoglobulins or glucocorticoids, with variable outcome; one patient was rechallenged with a different BRAFi\/MEKi combination with a rapid relapse in symptoms. In conclusion, patients under BRAFi\/MEKi therapy may develop treatment\u2010induced PN. Two main phenotypes can occur: a symmetric, axonal, length\u2010dependent polyneuropathy and a demyelinating polyradiculoneuropathy.<\/jats:p>","DOI":"10.1111\/bcp.15513","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T01:59:20Z","timestamp":1661565560000},"page":"4941-4949","source":"Crossref","is-referenced-by-count":12,"title":["Peripheral neuropathies after BRAF and\/or MEK inhibitor treatment: A pharmacovigilance study"],"prefix":"10.1111","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7807-5393","authenticated-orcid":false,"given":"Alberto","family":"Picca","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP\u2010HP, H\u00f4pitaux Universitaires La Piti\u00e9 Salp\u00eatri\u00e8re\u2010Charles Foix  Paris France"},{"name":"OncoNeuroTox Group, Center for Patients with Neurological Complications of Oncologic Treatments, GH Piti\u00e9\u2010Salp\u00eatri\u00e8re et H\u00f4pital Percy  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Birzu","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP\u2010HP, H\u00f4pitaux Universitaires La Piti\u00e9 Salp\u00eatri\u00e8re\u2010Charles Foix  Paris France"},{"name":"OncoNeuroTox Group, Center for Patients with Neurological Complications of Oncologic Treatments, GH Piti\u00e9\u2010Salp\u00eatri\u00e8re et H\u00f4pital Percy  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Berzero","sequence":"additional","affiliation":[{"name":"Neurology Unit IRCCS San Raffaele Scientific Institute  Milan Italy"},{"name":"Vita\u2010Salute San Raffaele University  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Sanchez\u2010Pena","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie m\u00e9dicale P\u00f4le de Sant\u00e9 Publique, CHU de Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Gaboriau","sequence":"additional","affiliation":[{"name":"Centre R\u00e9gional de Pharmacovigilance Service de Pharmacologie M\u00e9dicale, CHU de Lille  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faustine","family":"Vidil","sequence":"additional","affiliation":[{"name":"Agence National de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9  Saint\u2010Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timoth\u00e9e","family":"Lenglet","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Neurophysiologie Clinique AP\u2010HP, GH Piti\u00e9\u2010Salp\u00eatri\u00e8re  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Tafani","sequence":"additional","affiliation":[{"name":"OncoNeuroTox Group, Center for Patients with Neurological Complications of Oncologic Treatments, GH Piti\u00e9\u2010Salp\u00eatri\u00e8re et H\u00f4pital Percy  Paris France"},{"name":"D\u00e9partement de Neurologie, H\u00f4pital d'instruction des Arm\u00e9es Percy Service de Sant\u00e9 des Arm\u00e9es  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Ricard","sequence":"additional","affiliation":[{"name":"OncoNeuroTox Group, Center for Patients with Neurological Complications of Oncologic Treatments, GH Piti\u00e9\u2010Salp\u00eatri\u00e8re et H\u00f4pital Percy  Paris France"},{"name":"D\u00e9partement de Neurologie, H\u00f4pital d'instruction des Arm\u00e9es Percy Service de Sant\u00e9 des Arm\u00e9es  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Psimaras","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP\u2010HP, H\u00f4pitaux Universitaires La Piti\u00e9 Salp\u00eatri\u00e8re\u2010Charles Foix  Paris France"},{"name":"OncoNeuroTox Group, Center for Patients with Neurological Complications of Oncologic Treatments, GH Piti\u00e9\u2010Salp\u00eatri\u00e8re et H\u00f4pital Percy  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6797-0237","authenticated-orcid":false,"given":"K\u00e9vin","family":"Bihan","sequence":"additional","affiliation":[{"name":"OncoNeuroTox Group, Center for Patients with Neurological Complications of Oncologic Treatments, GH Piti\u00e9\u2010Salp\u00eatri\u00e8re et H\u00f4pital Percy  Paris France"},{"name":"D\u00e9partement de Pharmacologie, AP\u2010HP, GH Piti\u00e9\u2010Salp\u00eatri\u00e8re Centre r\u00e9gional de Pharmacovigilance  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.05.009"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(12)60868\u2010X"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112302"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904059"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(16)30122\u2010X"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(18)30497\u20102"},{"key":"e_1_2_10_8_1","unstructured":"European Medicines Agency: 04\/11\/2021 Zelboraf \u2013 EMEA\/H\/C\/002409 \u2013 N\/0060.Zelboraf: EPAR \u2013 Product Information \u2013 summary of product characteristics (annex I). Accessed August 10 2022.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zelboraf"},{"key":"e_1_2_10_9_1","unstructured":"European Medicines Agency: 25\/07\/2022 Braftovi \u2013 EMEA\/H\/C\/004580 \u2013 II\/0026.Braftovi: EPAR \u2013 Product information \u2013 summary of product characteristics (annex I). Accessed August 10 2022.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/braftovi"},{"key":"e_1_2_10_10_1","unstructured":"European Medicines Agency: 24\/01\/2022 Mektovi \u2013 EMEA\/H\/C\/004579 \u2013 IAIN\/0020.Mektovi: EPAR \u2013 Product information \u2013 summary of product characteristics (annex I). Accessed August 10 2022.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mektovi"},{"key":"e_1_2_10_11_1","unstructured":"European Medicines Agency: 19\/05\/2022 Cotellic \u2013 EMEA\/H\/C\/003960 \u2013 II\/0025.Cotellic: EPAR \u2013 Product information \u2013 summary of product characteristics (annex I). Accessed August 10 2022.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cotellic"},{"key":"e_1_2_10_12_1","unstructured":"European Medicines Agency: 14\/07\/2022 Mekinist \u2013 EMEA\/H\/C\/002643 \u2013 II\/0053\/G.Mekinist: EPAR \u2013 Product information \u2013 summary of product characteristics (annex I). Accessed August 10 2022.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mekinist"},{"key":"e_1_2_10_13_1","unstructured":"European Medicines Agency: 11\/11\/2021 Tafinlar \u2013 EMEA\/H\/C\/002604 \u2013 WS2114.Tafinlar: EPAR \u2013 Product information \u2013 summary of product characteristics (annex I). Accessed August 10 2022.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tafinlar"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061650"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.01.017"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.03.018"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000331"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072\u2010020\u201004604\u20101"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000390"},{"issue":"14","key":"e_1_2_10_20_1","article-title":"Guillain\u2010Barre syndrome after treatment with dabrafenib for metastatic recurrent melaloma. (P4.232)","volume":"84","author":"Maurice C","year":"2015","journal-title":"Neurology"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12337"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2016.02.010"},{"issue":"1","key":"e_1_2_10_23_1","first-page":"S313","article-title":"THE CONCISE GUIDE TO PHARMACOLOGY 2021\/22: Enzymes","volume":"178","author":"Alexander SP","year":"2021","journal-title":"Br J Pharmacol"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.4103\/0022\u20103859.132339"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn1898"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20131780"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2010.12.003"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4403\u201012.2013"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1515\/hsz\u20102015\u20100270"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ar.24126"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.19\u201002\u201000664.1999"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2010.09.028"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2015.06.003"},{"issue":"7","key":"e_1_2_10_34_1","first-page":"1239","article-title":"Trametinib suppresses chemotherapy\u2010induced cold and mechanical allodynia via inhibition of extracellular\u2010regulated protein kinase 1\/2 activation","volume":"8","author":"Tsubaki M","year":"2018","journal-title":"Am J Cancer Res"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.CAN\u201010\u20100118"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201012\u20101630"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2020.1723163"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102020\u2010323124"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2020.02.022"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15513","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15513","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T08:55:31Z","timestamp":1692608131000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1111\/bcp.15513"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15513","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,7]]}}}